let-363 Antibody
Product Specs
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Target Background
- Dafachronic acid signaling via let-363 is crucial for diet restriction-mediated longevity. PMID: 25209682
- Let-363 exerts a significant influence on lifespan. PMID: 14668850
- In C. elegans, the target of rapamycin (TOR) and the DAF-2/insulin-signaling pathways exhibit cross-talk with pep-2. PMID: 15155758
- Mutations in let-363 lead to dauer-like larval arrest, suggesting that CeTOR (let-363) regulates dauer diapause. PMID: 15253933
Q&A
Here’s a structured collection of FAQs tailored to academic research on the let-363 Antibody, integrating data and methodologies from peer-reviewed studies and patents:
Advanced Research Questions
How to resolve contradictory data in let-363-dependent lifespan studies?
Methodological Answer: Contradictions often arise from tissue-specific mTORC1 effects. Recommended approaches:
-
Tissue-selective degradation: Compare neuronal vs. somatic mTORC1 inhibition using rab-3 (neuronal) and eft-3 (somatic) promoters .
-
Dose-response analysis: Titrate auxin concentrations to modulate degradation efficiency (e.g., 0.1–1 mM auxin) .
Example Conflict Resolution:
A study reported inconsistent lifespan extension in cgef-1 mutants under let-363 RNAi. This was resolved by standardizing auxin exposure durations and normalizing to neuronal TIR1 expression levels .
What frameworks optimize humanized let-363 Antibodies for translational research?
Methodological Answer: Humanization strategies from antibody engineering patents include:
-
CDR grafting: Transplant non-human CDRs onto human frameworks while retaining critical FR residues (e.g., Kabat positions 4L, 36H) .
-
Affinity maturation: Use phage display libraries to improve binding after humanization .
Key Framework Residues for Stability:
| Chain | Critical Residues (Kabat numbering) | Function |
|---|---|---|
| Heavy | 24H, 49H, 93H | CDR anchoring |
| Light | 46L, 58L, 71L | FR-CDR interaction |
| Adapted from |
How to integrate let-363 Antibody studies with omics datasets?
Methodological Answer:
-
Transcriptomic correlation: Pair antibody-based mTORC1 activity assays with RNA-seq data from let-363 RNAi animals .
-
Proteomic validation: Use immunoprecipitation followed by mass spectrometry to identify mTORC1 interactomes under let-363 inhibition.
Data Contradiction Analysis Framework
For conflicting results (e.g., variable lifespan effects):
